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Anti-angiogenic drugs are approved for
the treatment of several cancer types,
generally in the inoperable locally
advanced or metastatic setting and in
combination with other anti-cancer
agents. Recent clinical studies also suggest
that anti-angiogenic drugs can be useful
in the pre-operative (neoadjuvant) setting,
by facilitating the shrinkage of the primary
tumour and its surgical resection. However,
the effects of neoadjuvant anti-angiogenic
therapy on the ability of tumours to form
distant metastases are unclear. In this
issue of EMBO Molecular Medicine, Ebos
et al (2014) present carefully performed
pre-clinical studies in mice that analyse the
effects of pre-operative anti-angiogenic
therapy on tumour metastasis and survival.
See also: JML Ebos et al
S everal angiogenesis inhibitors arecurrently employed for the treatmentof advanced and/or metastatic
cancer, often in combination with other anti-
cancer agents. Bevacizumab, a monoclonal
antibody that neutralizes the vascular-
endothelial growth factor (VEGF)-A, was the
first to receive approval in 2004. Among
other indications, it is now used in combina-
tion with chemotherapy for the first-line
treatment of metastatic colorectal and non-
small cell lung cancer and, as a single agent,
for recurrent glioblastoma. Other approved
anti-angiogenic agents include multi-kinase
inhibitors such as sunitinib and sorafenib,
which target the VEGF receptors (VEGFRs)
and other kinases with pro-angiogenic and
pro-proliferative functions (Sennino &
McDonald, 2012). Compared to the previous
standard of care, treatments based on angio-
genesis inhibitors provide benefits in terms
of objective response, which translate into
frequent but short-lived improvements in
progression-free and overall survival. The
lack of predictive biomarkers of response,
which may help identify patients who are
more likely to benefit, and the emergence of
resistance to therapy are believed to limit
the clinical efficacy of anti-angiogenic drugs
in late-stage cancer (Bergers & Hanahan,
2008; Sennino & McDonald, 2012).
Angiogenesis inhibitors are not yet
approved for the pre-operative (neoadju-
vant) treatment of resectable cancer. While
these drugs may promote the shrinkage and,
therefore, facilitate the surgical resection of
the tumour, concerns also exist that they
might concomitantly increase its propensity
to form distant metastasis. Indeed, studies in
mice have shown that tumour blood vessel
pruning may stimulate cancer cells to
acquire pro-invasive and metastatic traits, a
threatening form of tumour adaptation to
the hypoxic microenvironment (Sennino &
McDonald, 2012). Although these experi-
mental findings suggest that the immediate
benefits of pre-operative anti-angiogenic
therapy might be countered in the long term
by a heightened metastasis risk, a constella-
tion of parameters (e.g. drug mode of action,
dose and scheduling; combination with
other anti-cancer drugs; the cancer type/
model) may affect the metastatic behaviour
of the tumour on-treatment.
Ebos et al (2014) compared the effects of
different classes and dosage regimens of anti-
angiogenic drugs (including kinase inhibitors
and VEGFA/VEGFR blocking antibodies) and
a vascular-disrupting agent (OXi4503), alone or
in combination with low-dose cytotoxic chemo-
therapy (cyclophosphamide/5-fluorouracil), on
the metastatic spread of tumours treated
pre-operatively in mice. They employed
bioluminescent human cancer cell lines (rep-
resenting breast, melanoma and kidney
cancer) that spontaneously metastasize to
several organs when implanted orthotopically,
that is in their native site, in immunodeficient
mice. After surgical removal of the primary
tumour, the progressive growth of the metas-
tases was monitored in live mice by measuring
bioluminescence (Fig 1A). Termination criteria
were also established to determine mouse
survival.
The authors observed tumour-type and
drug-dependent effects of neoadjuvant anti-
angiogenic therapy on the development of
metastasis post-surgery (Fig 1B). For example,
high-dose (60 mg/kg) sunitinib—a broad-
spectrum kinase inhibitor that primarily
blocks the VEGFRs and platelet-derived
growth factor receptors (PDGFRs)—had
variable growth-inhibitory effects on the
different primary tumour models tested, but
consistently exacerbated post-surgery meta-
static growth and worsened survival. These
findings are in agreement with previous
studies that documented pro-metastatic
effects of high-dose sunitinib in non-surgical
tumour models (Ebos et al, 2009; Pa`ez-Ribes
et al, 2009; Chung et al, 2012). On the other
hand, all antibody-based VEGFA-pathway
inhibitors and high-dose (50 mg/kg)
OXi4503 had beneficial effects on both the
primary tumours and post-surgical metasta-
ses. Interestingly, the pro-metastatic effects
of sunitinib could be attenuated in a breast
cancer model by adopting a “condensed”
drug schedule, in which a further higher
dose (120 mg/kg) was administered for a
shorter time before surgery. Together, these
findings strongly suggest that the pro- versus
anti-metastatic activities of angiogenesis
inhibitors are drug-class and dose
dependent.
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The aforementioned observations are
certainly relevant and timely as ongoing clin-
ical trials evaluate the benefits of neoadju-
vant angiogenesis inhibitors in several
cancer types. Although survival data are not
yet available, two large randomized trials
documented a significant increase in the rate
of pathological complete response in breast
cancer after neoadjuvant bevacizumab plus
chemotherapy (Vasudev & Reynolds, 2014).
Furthermore, neoadjuvant sunitinib is being
investigated in breast cancer (NCT00656669)
and metastatic renal cell carcinoma (NCT01-
099423). The addition of bevacizumab to
neoadjuvant chemotherapy, however, increa-
sed the risk of surgical complications in
patients undergoing breast-conserving surgery
or repeated surgical procedures (Gerber et al,
2014). Because the half-life of bevacizumab is
about 2–3 weeks, performing surgery at least
6–8 weeks after the last bevacizumab infusion
should significantly reduce the occurrence of
such complications.
The findings of Ebos et al (2014) also
raise important questions, which should be
addressed in order to better appreciate the
clinical relevance and transferability of their
findings. For example, how do the dosage
regimens described by the authors compare
to those employed in patients? Daily doses
of sunitinib in the range of 60–120 mg/kg
are markedly higher than those administered
to cancer patients, so it is unclear whether
the reported dose-dependent effects on
metastatic growth in mice would be applica-
ble to the clinical setting. Moreover, it would
be of interest to see whether both the histo-
pathological responses in the primary
tumours and the systemic host responses
induced by sunitinib differ between the
“standard” and “condensed” regimens.
Sunitinib may alter tumour growth and
metastatic progression through several
mechanisms. Besides pruning intratumoural
blood vessels by inhibiting endothelial cell
proliferation (via VEGFR2 inhibition) and
depleting pericytes (via PDGFR inhibition),
sunitinib may have direct inhibitory effects
on cancer cells (e.g. via STAT3 inhibition)
as well as broader effects on a variety of
host (non-malignant) cells (Xin et al, 2009).
For example, it can prevent the activation of
the colony-stimulating factor-1 receptor
(CSF1R), which conveys essential pro-
survival signalling to monocytes and macro-
phages (Kitagawa et al, 2012). These cells
have important vascular-modulatory func-
tions and also appear to facilitate the estab-
lishment of metastasis by acting at different
steps during the metastatic cascade (Qian &
Pollard, 2010; Mazzieri et al, 2011). Because
sunitinib may inhibit different kinases dose
dependently and with variable potency, it is
tempting to speculate that—at the highest
doses tested in mice—it may have reversed
its pro-metastatic activity by impairing
STAT3-mediated survival of early-disseminated
cancer cells, or by depleting metastasis-
promoting, CSF1R-dependent inflammatory
monocytes.
Importantly, Ebos et al (2014) found that
low-dose chemotherapy (LDC) could help
improve the performance of neoadjuvant
sunitinib treatment by extending post-surgical
survival in a breast cancer model. Although
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Figure 1. Testing neoadjuvant anti-angiogenic therapies in an excisional breast cancer model.
(A) A human breast cancer cell line with metastatic capability is genetically modified with a luciferase construct to allow in vivo tracing. Primary tumour growth is initiated by
orthotopically transplanting the cancer cells in the mammary fat pad of severe combined immunodeficient (SCID) mice. Established tumours are then treated with specific
drug combinations, including anti-angiogenic agents. The primary tumours are removed and the subsequent formation of metastases is monitored by measuring luciferase
activity. (B) The therapeutic benefits of the distinct drugs—alone or in combination, and at different dosage regimens—on the primary tumours and post-surgical metastases
are shown (for details on dosage regimens and quantitative data, refer to Ebos et al (2014)). Note that Ebos et al (2014) investigated several tumour models; for the sake of
simplicity, only the breast cancer model is exemplified in the figure. LDC, low-dose chemotherapy (cyclophosphamide plus 5-fluorouracil).
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these findings need further validation,
they suggest that the complementary actions
of LDC and sunitinib on primary and
metastatic tumours can synergize to favour
both primary tumour responses and
outcome. Indeed, whereas LDC has negligi-
ble effects on primary tumour growth while
improving post-surgery survival, sunitinib
has marked effects on the primary tumour
but promotes post-surgical metastatic
dissemination. Therefore, drugs that can
prevent the dissemination and survival of
cancer cells may be combined with multi-
kinase angiogenesis inhibitors to improve
their safety. In this regard, inhibition of
angiopoietin-2 (a pro-angiogenic growth
factor that activates the TIE2 receptor) is
increasingly recognized as a dual angio-
inhibitory and anti-metastatic strategy
(Mazzieri et al, 2011; Rigamonti et al, 2014)
that might alleviate the risk of increased
metastasis associated with the use of more
potent angiogenesis inhibitors.
The majority of the experimental trials
reported by Ebos et al (2014) were
conducted in immunodeficient mice, which
lack an intact immune system. As a conse-
quence, the potentially important role
played by adaptive immune cells, such as T
and B lymphocytes, in the regulation of
tumour responses to anti-cancer therapies
needs to be studied more thoroughly in
immunocompetent mice. Regardless of the
current limitations, Ebos et al (2014)
convincingly show that, at least in mice,
primary tumour responses to neoadjuvant
anti-angiogenic therapy do not necessarily
predict post-surgical disease recurrence and
survival. Hopefully, the results of the ongoing
and future clinical studies will provide an
answer to the most important question of
all: does neoadjuvant anti-angiogenic ther-
apy increase the survival of cancer patients?
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